Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable,” suggesting that there could be a shift in fund flows towards different ...

Cantor Fitzgerald has a “Neutral” rating and a $110.00 price objective on the stock. The consensus estimate for Fortinet’s current full-year earnings is $2.05 per share. Get Fortinet alerts: ...

A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...

Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for AST SpaceMobile’s current full-year earnings is ($0.40) per share ...

Cantor Fitzgerald upgraded CVS Health (CVS) to Overweight from Neutral. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...

Cantor Fitzgerald upgraded McEwen Mining (MUX) to Buy from Speculative Buy with a $14.50 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top ...

Cantor Fitzgerald raised concerns about the Magnificent Seven stocks, suggesting they may be at risk of losing investor interest as fund flows shift to other sectors. Revenue projections for 2025 are ...

Howard Lutnick, the chairman of Cantor Fitzgerald and nominee for U.S. Commerce Secretary, faced questioning from Senate Democrats regarding the financial firm's investment in Tether, the entity ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC has several regulatory decisions this year ...

Get Our Latest Research Report on PI Impinj Stock Up 1.4 % Shares of NASDAQ:PI opened at $106.33 on Monday. The stock has a market cap of $3.01 billion, a PE ratio of 78.18 and a beta of 1.88 ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Surgery Partners (NASDAQ:SGRY) with a steady price target of $36.00. The stock, which has shown significant momentum with a 20% ...

On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen analyst targets ranging from ...